公开(公告)号：US11213499B1

公开(公告)日：2022-01-04

申请号：US17003420

申请日：2020-08-26

申请人： Secretary, Department of Atomic Energy

发明人： Amit Kunwar ,  Vishwa Vipulkumar Gandhi ,  Khushboo Atulkumar Gandhi ,  Vikram Suryaprakash Gota ,  Jayant Sastri Goda ,  Jyoti Anand Kode ,  Liladhar Baburao Kumbhare ,  Vimal Kumar Jain ,  Kavirayani Indira Priyadarsini

IPC分类号： A61K31/194 ,  A61P35/00

摘要： The present invention describes the method of using a synthetic organoselenium compound, DSePA for management of non-small cell lung carcinoma (NSCLC) and chronic myelogenous leukemia (CML). The method comprises administering DSePA orally at a dosage of 1 mg/Kg body weight daily for inhibiting the growth of A549 (representative of NSCLC) and K562 (representative of CML) tumor in mice models. Additionally, the said compound also inhibits the proliferation of other cancer cells of NSCLC (HOP-62 and H460), breast (MDA-MB-231), white blood cells (JURKAT and U-937), oral (SCC-40), colon (HT-29), kidney (A498) and cervix (SiHA) origins in cellular models at a much lower concentration than that needed to inhibit the growth of normal cells.